Physician profile
Blair Skolnick
NPI 1619039310
$4,294.13
in general payments reported to CMS, 2019-2025
16 companies · $732 in 2025
The $732 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $303 · 2021: $533 · 2022: $524 · 2023: $674 · 2024: $773 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.67 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $996.19 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $805.20 | 2019-2025 | Ingrezza |
| Abbvie INC. | $637.79 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $423.02 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $281.94 | 2019-2022 | |
| Lundbeck LLC | $270.27 | 2019-2024 | Rexulti |
| Alkermes, INC. | $235.15 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $228.32 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $134.37 | 2019-2020 | |
| Allergan, INC. | $74.13 | 2019-2020 | |
| Axsome Therapeutics, INC. | $54.50 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.50 | 2024 | Caplyta |
| Neuronetics, INC. | $34.25 | 2019 | |
| Validus Pharmaceuticals LLC | $25.00 | 2023 | Equetro |
| Supernus Pharmaceuticals, INC. | $24.75 | 2024 | Qelbree |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blair Skolnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.